Table 2.
Clinical, hormonal and neuroradiological evaluations in the long-term remission group compared to the group with disease relapse
| Long term remission | Disease relapse | p value | |
|---|---|---|---|
| Number of patients, n | 6 | 23 | NA |
| Age, years | 48 ± 17 | 51 ± 14 | 0.7 |
| Sex (M/F) | 1/5 | 7/16 | 0.6 |
|
Macro, n (%) Micro, n (%) No adenoma, n (%) |
5 (83) 1 (17) 0 |
14 (61) 7 (30) 2 (9) |
0.6 0.6 1.0 |
| TNS before SAs, n (%) | 5 (83) | 15 (65) | 0.6 |
| Hypopituitarism, n (%) | 2 (40) | 8 (33) | 1.0 |
| Duration of therapy, months | 64.6 ± 49 | 60.1 ± 38.8 | 1.0 |
| Hormonal data before starting SAs | |||
| IGF-1, SDS | 5.4 ± 2.3 | 6.2 ± 5 | 0.7 |
| Mean GH, ng/ml | 5.1 ± 3.3 | 6.3 ± 5.8 | 0.6 |
| GH nadir, ng/ml | 4.9 ± 5.6 | 5.7 ± 5.1 | 0.7 |
| Hormonal data before SAs withdrawal | |||
| IGF-1, SDS | −1.5 ± 0.6 | −0.11 ± 1 | 0.01* |
| Mean GH, ng/ml | 0.96 ± 0.45 | 0.96 ± 0.61 | 1.0 |
Data are expressed as number, percentage (%) and mean ± SDS; p-value is considered statistically significant if < 0.05
NA not applicable, Macro macroadenoma, Micro microadenoma, TNS transphenoidal surgery, SAs somatostatin analogues